Key Takeaways
- AstraZeneca (AZN) announced positive Phase III results for efzimfotase alfa (ALXN1850), achieving a median RGI-C score of 1.67 versus 0.00 for placebo in pediatric patients with hypophosphatasia (HPP).
- The White House expressed concern that the United Kingdom may fail to honor its pledge to raise defense spending to 5% of GDP, warning of potential "false promises" made to satisfy the Trump administration.
- Incoming Prime Minister Andy Burnham is expected to postpone setting a firm date for reaching a 3% GDP defense spending target in an upcoming government plan, despite signaling broad support for the military.
- AstraZeneca (AZN) estimates peak annual sales for its new HPP therapy could reach between $3 billion and $5 billion, significantly higher than the $1.7 billion generated by its predecessor, Strensiq.
AstraZeneca Achieves Clinical Milestone in Rare Bone Disease
AstraZeneca (AZN) and its rare disease unit, Alexion, reported successful outcomes from the MULBERRY Phase III trial evaluating efzimfotase alfa (ALXN1850). The investigational enzyme replacement therapy demonstrated a statistically significant improvement in bone health for children aged 2 to 12 with hypophosphatasia (HPP).
The study met its primary endpoint with a median Radiographic Global Impression of Change (RGI-C) score of 1.67 compared to 0.00 for the placebo group at week 25. Furthermore, the trial achieved a key secondary endpoint in bone health as measured by the Rickets Severity Score (RSS), showing a median difference of -1.00 against placebo. These results support the potential for a self-administered treatment taken every two weeks, offering a more convenient dosing schedule than current therapies.
Transatlantic Tensions Rise Over UK Defense Commitments
The White House has signaled growing skepticism regarding the United Kingdom's ability to deliver on a high-profile pledge to increase defense expenditures to 5% of GDP. According to reports from The Telegraph, U.S. officials are concerned that some European allies may have made "false promises" to appease President Donald Trump during recent negotiations.
The 5% target—composed of 3.5% for core defense and 1.5% for resilience—was established under pressure to increase burden-sharing within NATO. U.S. administration officials are reportedly reviewing the American military footprint in Europe, suggesting that assets could be relocated if allies do not meet these aggressive rearmament goals.
Political Transition in UK Impacts Defense Strategy
Concerns are mounting as Andy Burnham prepares to succeed Keir Starmer as Prime Minister. While Burnham has indicated support for elevated military funding, the upcoming government defense plan is expected to avoid committing to a specific timeline for reaching 3% of GDP in spending.
This expected postponement has drawn criticism from defense advocates who argue that a lack of a clear trajectory undermines the UK's standing within NATO. The delay comes amid significant fiscal constraints and internal political pressure to prioritize social spending over military expansion, potentially complicating the UK's relationship with the Trump administration ahead of the upcoming NATO summit in Ankara.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.